Centene Corporation (CNC) Analyst Ratings & Price Targets

Centene Corporation

CNC · NYSE

Analyst Consensus

Hold

20 analysts

$69

Current

—

Low

$71

Average

—

High

Average target implies +2.31% versus the current price.

Analyst Ratings Synthesis

Consensus is Hold across 20 analysts, with a mean price target of $70.5. The supplied consensus does not report a low or high target, so target clustering and the full spread cannot be assessed. No named analyst is identified as the most or least bullish, and no rating or target revisions are supplied for the past week; therefore, the direction of revisions is unavailable. The substantive contrast in the evidence is editorial rather than analyst-specific: Zacks presents Centene as a value and momentum opportunity, while its UnitedHealth comparison says UnitedHealth has the stronger long-term managed-care outlook. No attributable broker disagreement is documented.

Rating Actions

No individual rating actions have been captured for CNCyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BARCLAYS CAPITA

CANTOR FITZGERA

CO FORECST

DEUTSCHE BK SEC

GOLDMAN SACHS

JEFFERIES & CO.

JP MORGAN SECUR

LOOP CAPITAL MK

MIZUHO SECURITI

OPPENHEIMER HLD

SANFORD BERNSTE

STEPHENS INC

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: CNC
Type: Stock
Sector: Health Care
Industry: Hospital & Medical Service Plans
Exchange: NYSE

Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach - with local brands and local teams - to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans), as well as individuals and families served by the Health Insurance Marketplace.

Key Issues

Bullish view

Zacks identifies Centene as a strong value stock and includes it among GARP candidates with discounted PEG ratios and long-term growth potential. That framing suggests the valuation may already reflect substantial concerns.

Bearish view

Centene’s financial trend weakened sharply, with fiscal 2025 revenue of $174.6 billion accompanied by a $6.7 billion net loss, versus $3.3 billion of net income in fiscal 2024. The loss makes the value case dependent on a demonstrated earnings recovery that the supplied evidence does not document.

Analyst Consensus

See all

Hold

20 analysts

$69

Current

—

Low

$71

Average

—

High

Average target implies +2.31% versus the current price.

Earnings History

BeatMissNo estimate

Centene Corporation

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers